What is Humacyte Inc (HUMA) stock price today?

Humacyte Inc (HUMA) currently trades at $0.84 per share. The stock has a market capitalization of $178.93M and a P/E ratio of —x.

Is HUMA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Humacyte Inc has a Smart Value Score of 14/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Humacyte Inc's revenue and earnings?

Humacyte Inc has trailing twelve-month (TTM) revenue of $2.04M with profit margins of 0.00%. Earnings per share (EPS) is $-0.26.

Is HUMA stock overvalued or undervalued?

Based on our DCF model, Humacyte Inc's intrinsic value is $2.42, representing a margin of safety of 58.26%. The stock currently trades at a P/E of —x.

HUMA

Humacyte Inc

NASDAQ: HUMA · HEALTHCARE · BIOTECHNOLOGY

$0.84

+2.66% today

Updated 2026-04-30

Market cap

$178.93M

P/E ratio

—

P/S ratio

87.79x

EPS (TTM)

$-0.26

Dividend yield

—

52W range

$1 – $3

Volume

6.7M

Market cap

$178.93M

P/E ratio

—

P/S ratio

87.79x

EPS (TTM)

$-0.26

Dividend yield

—

52W range

$1 – $3

Volume

6.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.0

Growth

5.0

Quality

C+

2.5

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.10

+505.84%

12-Month target

—

Intrinsic (DCF)

$2.42

Margin of safety

+58.26%

2 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 58.26% below intrinsic value

Risks

- Thin margins at 0.00%

- Negative free cash flow $-26.16M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.56M	$0.00	$0.00	$2.04M	$2.04M
Net income	$-11.96M	$-110.78M	$-148.70M	$-40.83M	$-24.80M
EPS	—	—	—	—	$-0.26
Free cash flow	$-72.18M	$-75.58M	$-99.69M	$-105.93M	$-26.16M
Profit margin	-764.54%	—	—	-2,003.58%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
HUMA	$178.93M	14	4.0	2.5	6.7	5.0	+58.26%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Humacyte Inc trades at $0.84. Our Smart Value Score of 14/100 indicates the stock is weak. TTM revenue stands at $2.04M. Our DCF model estimates intrinsic value at $2.42.

Frequently asked questions

What is Humacyte Inc's stock price?

Humacyte Inc (HUMA) trades at $0.84.

Is Humacyte Inc overvalued?

Smart Value Score 14/100 (Grade F, Strong Sell). DCF value $2.42.

What is the price target of Humacyte Inc (HUMA)?

The analyst target price is $5.10, representing +505.8% upside from the current price of $0.84.

What is the intrinsic value of Humacyte Inc (HUMA)?

Based on our DCF model, intrinsic value is $2.42, a +58.3% margin of safety versus $0.84.

What is Humacyte Inc's revenue?

TTM revenue is $2.04M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio87.79x

ROE-249.80%

Beta2.11

50D MA$0.90

200D MA$1.38

Shares out0.22B

Float0.19B

Short ratio—

Avg volume6.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

HUMA vs LLY →HUMA vs JNJ →HUMA vs ABBV →Stock screener →